Mometasone Nasal Spray:
- 50 mcg - Mometasone Furoate Monohydrate USP;
Mometasone Furoate Monohydrate:
- 0.05% w/v - Mometasone Furoate USP;
- 0.01% w/v - Benzalkonium Chloride NF;
- 0.25% v/v - Phenyl Ethyl Alcohol USP;
Without a Prescription
Mometasone nasal spra y is prescribed for the treatment of seasonal and perennial allergic rhinitis symptoms in adults and
paediatric patients, 2 years of age and older. Mometasone nasal spray is prescribed for the prophylaxis of seasonal allergic
rhinitis symptoms in adult and adolescent patients, 12 years and older. Mometasone nasal spray is also prescribed in the
treatment of nasal polyps in those aged 18 and above.
After initial priming of the Mometasone Nasal Spray pump (usually, 6 or 7 actuations, until a uniform spray is observed),
each actuation delivers approximately 100 mg of mometasone furoate suspension, containing mometasone furoate monohydrate
equivalent to 50 mcg mometasone furoate. If the spray pump has not been used for 14 days or longer, it should be reprimed
before the next use.
Seasonal or Perennial Allergic Rhinitis
Adults (Including Geriatric Patients) and Adolescents (12 Years Of Age and Older):
The usual recommended dose is two sprays (50 mcg/spray) in each nostril once daily (total dose of 200 mcg). Once symptoms are controlled, dose reduction to one spray in each nostril (total dose of 100 mcg) may be effective for maintenance.
If symptoms are inadequately controlled, the dose may be increased to a maximum dose of four sprays in each nostril once daily (total dose of 400 mcg). Dose reduction is recommended following control of symptoms.
Children (Between the Ages of 6-11 Years):
The usual recommended dose is one spray (50 mcg/spray) in each nostril once daily (total dose of 100 mcg).
Mometasone Nasal Spray demonstrated a clinically significant onset of action within 12 hours after the first dose in some patients with seasonal allergic rhinitis; however, the full benefit of the treatment may not be achieved in the first 48 hours. Therefore, the patient should continue regular use to achieve full therapeutic benefit.
The usual recommended starting dose for polyposis is two sprays (50 mcg/spray) in each nostril once daily (total daily dose of 200 mcg). If after 5-6 weeks, symptoms are inadequately controlled, the dose may be increased to a dose of two sprays in each nostril twice daily (total daily dose of 400 mcg). The dose should be reduced following control of symptoms. If no improvement in symptoms is seen after 5-6 weeks of twice-daily administration, alternative therapies should be considered.
Hypersensitivity to any of the ingredients of this preparation contraindicates its use.
Pack contains 100 metered doses.